Rankings
▼
Calendar
ALKS Q3 2018 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q3 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$249M
+14.4% YoY
Gross Profit
$209M
84.2% margin
Operating Income
-$37M
-14.9% margin
Net Income
-$34M
-13.8% margin
EPS (Diluted)
$-0.22
QoQ Revenue Growth
-18.4%
Cash Flow
Operating Cash Flow
$33M
Free Cash Flow
$17M
Stock-Based Comp.
$25M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$610M
Stockholders' Equity
$1.2B
Cash & Equivalents
$216M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$249M
$217M
+14.4%
Gross Profit
$209M
$181M
+15.4%
Operating Income
-$37M
-$38M
+3.1%
Net Income
-$34M
-$36M
+5.1%
Revenue Segments
Vivitrol
$80M
39%
Invega Sustenna Or Xeplion And Invega Trinza
$66M
32%
Aristada
$36M
17%
B Y D U R E O N
$12M
6%
A M P Y R A Or F A M P Y R A
$7M
4%
R I S P E R D A L C O N S T A
$4M
2%
Other Products And Services
$2M
1%
← FY 2018
All Quarters
Q4 2018 →